{"classes":[{"categories":[{"measurements":[{"comment":"Median and upper CI was not estimable due insufficient number of events.","groupId":"OG000","lowerLimit":"20.3","upperLimit":"NA","value":"NA"},{"comment":"Median and upper CI was not estimable due insufficient number of events.","groupId":"OG001","lowerLimit":"12.6","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"208"},{"groupId":"OG001","value":"90"}],"units":"Participants"}],"title":"BICR"},{"categories":[{"measurements":[{"comment":"Median and upper CI was not estimable due insufficient number of events.","groupId":"OG000","lowerLimit":"20.8","upperLimit":"NA","value":"NA"},{"comment":"Median and upper CI was not estimable due insufficient number of events.","groupId":"OG001","lowerLimit":"14.1","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"201"},{"groupId":"OG001","value":"97"}],"units":"Participants"}],"title":"Investigator Assessment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"261"},{"groupId":"OG001","value":"263"}],"units":"Participants"}],"description":"Duration of Response (DoR) was defined as the time from the date of the first documentation of objective response (complete response \\[CR\\] or partial response \\[PR\\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DoR in participants with confirmed CR/PR based on BICR and investigator assessment is reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DXd as a sterile intravenous (IV) solution at a dose of 5.4 mg/kg every 3 weeks (Q3W).","id":"OG000","title":"Trastuzumab Deruxtecan (T-DXd)"},{"description":"Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DM1 in accordance with the approved label.","id":"OG001","title":"Ado-trastuzumab Emtansine (T-DM1)"}],"paramType":"MEDIAN","populationDescription":"Duration of Response (DoR) was assessed in the Full Analysis Set of participants with confirmed CR/PR at data cut-off date of 21 May 2021.","reportingStatus":"POSTED","timeFrame":"Up to 33 months (data cut-off)","title":"Duration of Response (DoR) Based on BICR and Investigator Assessment in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane","type":"SECONDARY","unitOfMeasure":"months"}